Renal cell carcinoma (advanced) - evaluation report

01a - Final updated post-appeal Scope

01b- Final updated post-appeal Matrix of Consultees and Commentators

02- Post-appeal Manufacturer/sponsor addendum submission- Pfizer

03a - NICE request to the manufacturer for clarification

on their submission

03b- Manufacturer clarification response

04a- Post-appeal patient group submission- James Whale Fund for Kidney Cancer

04b- Post-appeal patient group submission-  Kidney Cancer Support Network

05a- Post-appeal Patient expert personal perspective- Hanlon

05b- Post-appeal Clinical expert personal perspective-Hawkins

06- Post-appeal Evidence Review Group report addendum factual accuracy check  prepared by

Kleijnen Systematic Reviews

07-Post-appeal Erratum to the Evidence Review Group report addendum prepared by Kleijnen Systematic Reviews

08-Post-appeal Grunwald abstract summary prepared by Pfizer

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 03 March 2014